FDA Approves First Blood Test for Multiple Hereditary Cancers by Invitae, Boosting Stock

The FDA has approved the first blood test, called the Invitae Common Hereditary Cancers Panel, that can identify DNA variants in 47 genes associated with an elevated risk of developing certain types of cancer. The test uses next-generation sequencing to assess multiple genes in a single test, providing insight into genetic variants with sensitivity and speed. The approval aims to improve the identification of hereditary cancer variants and increase testing rates. However, there are risks of false positive or false negative results, as well as potential misunderstanding of the test results.